Context Therapeutics Files 8-K with Regulatory Disclosures
Ticker: CNTX · Form: 8-K · Filed: 2026-04-02T07:41:09-04:00
Sentiment: neutral
Topics: regulatory-disclosure, filing, exhibit
Related Tickers: CTX
TL;DR
CTX shares might move on new 8-K filing - check EX-99.1 for details.
AI Summary
On April 2, 2026, Context Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing includes an exhibit, EX-99.1, titled 'a04022026fasttrackdesignat.htm', and various XBRL documents.
Why It Matters
This 8-K filing indicates that Context Therapeutics Inc. is making public disclosures and providing updated financial information, which could be relevant for investors monitoring the company's activities.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant financial distress or major corporate changes.
Key Numbers
- 25511 — iXBRL 8-K Size (Size of the main 8-K document in bytes.)
- 11745 — EX-99.1 Size (Size of the exhibit EX-99.1 in bytes.)
Key Players & Entities
- Context Therapeutics Inc. (company) — Filer of the 8-K report
- 0001842952 (company) — CIK number for Context Therapeutics Inc.
- 2026-04-02 (date) — Filing date of the 8-K report
- EX-99.1 (document) — An exhibit filed with the 8-K
FAQ
What specific information is contained in the exhibit EX-99.1?
The filing does not detail the specific content of EX-99.1, only that it is an exhibit to the 8-K filing.
What are the primary items disclosed in this 8-K filing?
The filing covers Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026, at 07:41:09.
What is the business address of Context Therapeutics Inc.?
The business address is 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103.
What is the SIC code for Context Therapeutics Inc.?
The SIC code is 2834, categorized under Pharmaceutical Preparations.
From the Filing
EDGAR Filing Documents for 0001628280-26-022931 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001628280-26-022931 Filing Date 2026-04-02 Accepted 2026-04-02 07:41:09 Documents 13 Period of Report 2026-04-02 Items Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K cntx-20260402.htm iXBRL 8-K 25511 2 EX-99.1 a04022026fasttrackdesignat.htm EX-99.1 11745 6 image_0.jpg GRAPHIC 198394 Complete submission text file 0001628280-26-022931.txt 440899 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20260402.xsd EX-101.SCH 1818 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20260402_lab.xml EX-101.LAB 24372 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20260402_pre.xml EX-101.PRE 14143 16 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20260402_htm.xml XML 3001 Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416 Context Therapeutics Inc. (Filer) CIK : 0001842952 (see all company filings) EIN. : 863738787 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 26830641 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)